

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original): A polymorphic form of 3-phenylsulfonyl-8-piperazin-1-yl-quinoline characterised in that it provides:
 - (i) an infrared spectrum containing peaks at 724, 758, 777, 804, 818, 838, 856, 905, 918, 948, 1023, 1055, 1081, 1092, 1118, 1136, 1153, 1178, 1244, 1302, 1318, 1365, 1378, 1403, 1444, 1471, 1490, 1569, 1584, 1603 and 2819 cm^{-1} ; and/or
 - (ii) a Raman spectrum containing peaks at 159, 184, 214, 241, 285, 304, 318, 429, 545, 558, 614, 706, 724, 803, 856, 1000, 1023, 1080, 1093, 1136, 1152, 1233, 1243, 1317, 1343, 1364, 1378, 1403, 1446, 1569, 1584, 1602, 3050 and 3073 cm^{-1} ; and/or
 - (iii) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings at 10.29 , 11.94 , 17.47 , 19.55 , 19.84 , and 20.33° ; and/or
 - (iv) a melting point of 188°C .
2. (Original): A polymorph according to claim 1 which provides an infrared spectrum substantially in accordance with Figure 1.
3. (Currently amended): A polymorph according to claim 1 ~~or claim 2~~ which provides a Raman spectrum substantially in accordance with Figure 2.
4. (Currently amended): A polymorph according to claim 1 ~~any one of claims 1 to 3~~ which provides an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings at 10.29 , 10.76 , 11.94 , 14.33 , 14.61 , 14.93 , 16.02 , 16.80 , 17.47 , 17.92 , 19.13 , 19.55 , 19.84 , 20.33 , 21.16 , 21.36 , 23.33 , 23.96 , 24.44 , 24.67 , 25.51 , 26.12 , 27.13 , 27.77 , 28.06 , 28.35 , 29.23 , 29.46 , 30.06 , 30.35 , 31.27 , 32.35 , 32.66 , 33.08 , 33.77 , 34.49 , 35.18 , 36.42 , 37.34 , 38.39 and 39.51° .

5. (Currently amended): A polymorph according to claim 1 ~~any one of claims 1 to 4~~ which provides an X-ray powder diffraction (XRPD) pattern substantially in accordance with Figure 3.

6. (Currently amended): A polymorph according to claim 1 ~~any one of claims 1 to 5~~, in isolated form.

7. (Currently amended): A polymorph according to claim 1 ~~any one of claims 1 to 5~~, in pure form.

8. (Currently amended): A polymorph according to claim 1 ~~any one of claims 1 to 5~~, in crystalline form.

9. (Currently amended): A pharmaceutical composition which comprises a polymorph according to claim 1 ~~any one of claims 1 to 8~~ and a pharmaceutically acceptable carrier or excipient.

10. (Currently amended): A polymorph according to claim 1 ~~any one of claims 1 to 8~~ for use in therapy.

Claims 11-12 (Cancelled).

13. (Currently amended): A pharmaceutical composition comprising a polymorph according to claim 1 ~~any one of claims 1 to 8~~ for use in the treatment of depression, anxiety, Alzheimers disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke.

14. (Currently amended): A method of treating depression, anxiety, Alzheimers disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke which comprises administering a safe and therapeutically effective amount to a patient in need thereof of a polymorph according to claim 1 ~~any one of claims 1 to 8~~.

15. (Currently amended): A method of promoting neuronal growth within the central nervous system of a mammal which comprises the step of administering a polymorph according to claim 1 ~~any one of claims 1 to 8~~.

Claim 16 (Cancelled).

17. (Currently amended): A pharmaceutical composition comprising a polymorph according to claim 1 ~~any one of claims 1 to 8~~ for use in promoting neuronal growth within the central nervous system of a mammal.